Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.51 |
| ▸ | MMP3 | P08254 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | HRH2 | P25021 | 4/20 | 0.47 |
| ▸ | HRH1 | P35367 | 4/20 | 0.47 |
| ▸ | MMP2 | P08253 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5522642 | 1.00 | HRH3 (0.57) | HRH3ALDH1A1MAPTHDAC1HDAC2 | |
| SCHEMBL14448890 | 1.00 | HRH3 (0.57) | HRH3ALDH1A1MAPTHDAC1HDAC2 | |
| SCHEMBL3107072 | 1.00 | HRH3 (0.57) | HRH3ALDH1A1MAPTHDAC1HDAC2 | |
| SCHEMBL22401643 | 1.00 | HRH3 (0.57) | HRH3ALDH1A1MAPTHDAC1HDAC2 | |
| SCHEMBL11031564 | 1.00 | HRH3 (0.57) | HRH3ALDH1A1MAPTHDAC1HDAC2 | |
| SCHEMBL1713933 | 0.98 | ALDH1A1 (0.54) | HRH3ALDH1A1MAPTHDAC1HDAC2 | |
| SCHEMBL5097451 | 0.95 | HDAC1 (0.58) | HRH3ALDH1A1HDAC1HDAC2MMP3 | |
| SCHEMBL9227809 | 0.95 | HDAC1 (0.58) | HRH3ALDH1A1HDAC1HDAC2MMP3 | |
| SCHEMBL2201281 | 0.95 | HDAC1 (0.58) | HRH3ALDH1A1HDAC1HDAC2MMP3 | |
| SCHEMBL6709272 | 0.95 | HDAC1 (0.58) | HRH3ALDH1A1HDAC1HDAC2MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388542-A1 | ANALOGUES OF PENTAMIDINE AND USES THEREFOR | AURANSA INC. (US) | 2025-12-25 | — | — | US | disclosed |
| CN-113766914-B | Pentaneamidine analogues and uses thereof | 美商奥润沙公司 | 2024-02-13 | — | — | CN | disclosed |
| US-20220144776-A1 | ANALOGUES OF PENTAMIDINE AND USES THEREFOR | AURANSA INC. | 2022-05-12 | — | — | US | disclosed |
| CN-113766914-A | Pentamidine analogs and uses thereof | 美商奥润沙公司 | 2021-12-07 | — | — | CN | disclosed |
| EP-3897600-A1 | ANALOGUES OF PENTAMIDINE AND USES THEREFOR | Auransa Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| WO-2020132636-A1 | ANALOGUES OF PENTAMIDINE AND USES THEREFOR | AURANSA INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020132636-A1 | ANALOGUES OF PENTAMIDINE AND USES THEREFOR | AURANSA INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| US-7960417-B2 | Such as 1-(2,2-dimethylpropyl)-4-propyl-5-{4-[4-(1H-tetrazol-5-yl)phenoxy]butoxy}-1H-indole; neurological and psychiatric disorders | MERCK SHARP & DOHME CORP. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20080176904-A1 | Benzazole Potentiators of Metabotropic Glutatmate Receptors | MERCK SHARP & DOHME CORP. | 2008-07-24 | — | — | US | disclosed |
| EP-1855670-A2 | BENZAZOLE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Merck & Co., Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| US-6153613-A | 2,3-diketopiperazine derivatives or their salts | TOYOMA CHEMICAL CO., LTD. (JP) | 2000-11-28 | — | — | US | disclosed |
| US-5877174-A | ANTICOAGULANTS | TOYAMA CHEMICAL CO., LTD. (JP) | 1999-03-02 | — | — | US | disclosed |
| EP-0669909-B1 | SUBSTITUTED AMIDINO COMPOUNDS, THEIR MANUFACTURE AND METHODS OF TREATMENT | CIBA GEIGY AG (CH) | 1998-01-07 | — | — | EP | disclosed |
| EP-0805149-A1 | NOVEL 2,3-DIKETOPIPERAZINE DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 1997-11-05 | — | — | EP | disclosed |
| US-5639768-A | LEUKOTOTRIENE RECEPTOR ANTAGONIST; ANTINFLAMMATORY AGENTS | CIBA-GEIGY CORPORATION (US) | 1997-06-17 | — | — | US | disclosed |
| US-5451700-A | Leukotriene inhibitors | CIBA-GEIGY CORPORATION (US) | 1995-09-19 | — | — | US | disclosed |
| EP-0669909-A1 | SUBSTITUTED AMIDINO COMPOUNDS, THEIR MANUFACTURE AND METHODS OF TREATMENT | Novartis AG (CH) | 1995-09-06 | — | — | EP | disclosed |
| WO-1994011341-A1 | SUBSTITUTED AMIDINO COMPOUNDS, THEIR MANUFACTURE AND METHODS OF TREATMENT | CIBA-GEIGY AG (CH) | 1994-05-26 | — | — | WO | disclosed |
| EP-0111345-A2 | Isoxazoles, useful as antiviral agents, and preparation thereof | STERLING DRUG INC. (US) | 1984-06-20 | — | — | EP | disclosed |
| US-4451476-A | Isoxazoles as antiviral agents | STERLING DRUG INC. (US) | 1984-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388542-A1 | ANALOGUES OF PENTAMIDINE AND USES THEREFOR | MALT1, SLC38A7, SLC7A1 | HRH3 474/4885ALDH1A1 1716/4885MAPT 4809/4885 |
| US-20220144776-A1 | ANALOGUES OF PENTAMIDINE AND USES THEREFOR | DPYD, TYMP, GOT1 | HRH3 2911/4885ALDH1A1 719/4885MAPT 3836/4885 |
| US-20080176904-A1 | Benzazole Potentiators of Metabotropic Glutatmate Receptors | GRM2, GRM3, GRIK2 | HRH3 415/4885ALDH1A1 2230/4885MAPT 2034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.